2024.12.18
筆頭著者 盛田大介 先生の論文が Journal for ImmunoTherapy of Cancer 誌に掲載されました。
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
